Blood-based tumour profiling provides less-invasive option for treatment-resistant prostate cancer

Date Posted: 
2017-06-29

The Journal of the National Cancer Institute today published a landmark multi-institutional study describing the first comprehensive comparison of blood-based tumour biopsy versus metastatic tissue biopsy for lethal prostate cancer.

Led by Vancouver Prostate Centre PIs Wyatt, Chi and Gleave, this study showed that a blood-based test can identify all the important driver mutations that are detected in a tissue biopsy. This paves the way for blood-based tumour profiling to replace the need for the metastatic tissue biopsy in prostate cancer patients with treatment-resistant disease.

The work was funded by a Stand Up to Cancer Prostate Cancer Foundation Prostate Dream Team Translational Cancer Research Grant, with additional support provided by Prostate Cancer Canada through the Movember Rising Star in Prostate Cancer research program (AW), the Emil Aaltonen Foundation (MA), and a Terry Fox New Frontiers Program Project.

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer 
Alexander W. Wyatt, Matti Annala, Rahul Aggarwal, Kevin Beja, Felix Feng, Jack Youngren, Adam Foye, Paul Lloyd, Matti Nykter, Tomasz M. Beer, Joshi J. Alumkal, George V. Thomas, Robert E. Reiter, Matthew B. Rettig, Christopher P. Evans, Allen C. Gao, Kim N. Chi, Eric J. Small, Martin E. Gleave

 

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Terry Fox Run, Sunday September 17

The Terry Fox Walk/Run for Prostate Cancer takes place on Sunday September 17. The Vancouver Prostate Centre team page is open for those who wish to join or donate.

Employment

Work at the Vancouver Prostate Centre

Monday, January 30, 2017

Dr. Amina Zoubeidi leads identification of gene linked to growth of aggressive neuroendocrine prostate cancer (NEPC)

DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.